(P1316)
|
Treatment of In-Stent Restenosis with Drug-Eluting Stents: Results from the Prospective Multicentre German Drug-Eluting Stent Registry
|
|
M. Abdel-Wahab, C. Nienaber, S. Silber, G. Sabin, C. Bode, U. Tebbe, M. Hochadel, J. Senges, G. Richardt on behalf of DES.DE (Bad Segeberg, Rostock, München, Essen, Freiburg im Breisgau, Detmold, Ludwigshafen)
|
(P1317)
|
In-Stent Restenosis: Outcome with Paclitaxel versus Everolimus Eluting Stents
|
|
J. Wöhrle, M. Kochs, V. Hombach (Ulm)
|
(P1318)
|
Recurrent Restenosis After Drug-Eluting-Stents Implantation in a Cohort of 5595 Lesions
|
|
J. Mehilli, K. Tiroch, S. Massberg, S. Schulz, O. Bruskina, J. Pache, M. Seyfarth, A. Kastrati, A. Schömig (München)
|
(P1319)
|
Differential Effect of Stent Length on Outcome after Percutaneous Coronary Intervention Using the Sirolimus-Eluting Stent: 5 Year Results from the Prospective Multicentre German Cypher Stent Registry
|
|
M. Abdel-Wahab, C. W. Hamm, J. Senges, R. Zahn, U. Tebbe, M. Horack, A. Loewe, T. Pfannebecker, B. Levenson, G. Richardt (Bad Segeberg, Bad Nauheim, Ludwigshafen, Detmold, Berlin, Langenfeld)
|
(P1320)
|
Long-term outcome after drug-eluting stenting versus bare-metal stenting i patients with ST-elevation myocardial infarction treated with primary PCI in Sweden
|
|
J. Carlsson, J. Nilsson, B. Lagerqvist, O. Fröbert, S. James on behalf of SCAAR Studiengruppe (Kalmar, Umeå, Uppsala, Örebro, SE)
|
(P1321)
|
Long-term Cost-Effectiveness of Sirolimus-Eluting Versus Bare-Metal Stents: 36-month Results of the GERSHWIN Study
|
|
S. N. Willich, D. McBride, S. Roll, C. Bode, C. W. Hamm, K.-H. Kuck, B. Brüggenjürgen (Berlin, Freiburg im Breisgau, Bad Nauheim, Hamburg)
|
(P1322)
|
Comparison of outcomes of 1,809 patients treated with drug-eluting stents and bare-metal stents in a routine setting
|
|
A. Vogt, M. Schlitt, A. Schoelmerich, F. Pollner, U. Raaz, A. Plehn, I. K. Reindl, M. Buerke, K. Werdan, A. Schlitt (Halle/Saale)
|
(P1323)
|
Comparative Antirestenotic Efficacy Of Biodegradable Polymer And Permanent Polymer Drug-eluting Stents: The Angiographic Follow-up Results Of The ISAR-TEST-4 Randomized Trial
|
|
S. Kufner, R. A. Byrne, S. Schulz, K. A. Birkmeier, K. Tiroch, S. Piniek, S. Hurt, J. Pache, J. Mehilli (München)
|
(P1324)
|
Die Wirksamkeit und Sicherheit des polymerfreien Sirolimusfreisetzenden Stent-Systems aus In-Haus-Herstellung in unselektierten Patienten: die Ergebnisse aus dem YUKON DES Register
|
|
J. Yu, M.-A. Ohlow, H. von Korn, M. Schreiber, A. Wagner, J. T. Fuhrmann, B. Buchter, Y. Daralammouri, W. Schulte, B. Lauer (Bad Berka, Neustadt, Friedrichroda)
|
(P1325)
|
Novel Paclitaxel-Eluting Coronary Stent with Abluminal Bioabsorbable Polymer: Results from “Jactax HD™” Prospective, Non-Randomized, Single arm, Multi-Center Trial
|
|
T. Tübler, E. Grube, K. E. Hauptmann, J. Schofer (Hamburg, Siegburg, Trier)
|
(P1326)
|
Six-month follow-up of RES-ELUTION NEVO-I, A Randomized Multi-Center Comparison of the Nevo Reservoir-Based Sirolimus-Eluting Stent with the TAXUS Liberte Paclitaxel-Eluting Stent
|
|
J. Schofer, A. Abizaid, J. Fajadet, J. Ormiston, H.-P. Stoll, C. Spaulding (Hamburg; Sao Paolo, BR; Toulouse, Paris, FR; Auckland, NZ; Waterloo, BE)
|
(P1327)
|
Prospective, Randomized Trial of Paclitaxel- versus Sirolimus-Eluting Stents for Treatment of Coronary Restenosis in Sirolimus-Eluting Stents: ISAR-DESIRE 2
|
|
J. Mehilli, S. Schulz, K. Tiroch, K. A. Birkmeier, M. Seyfarth, R. A. Byrne, J. Pache, S. Massberg, A. Schömig, A. Kastrati (München)
|
(P1328)
|
Clinical and angiographic outcomes of patients with coronary instent-restenoses (ISR) treated with local delivery of fluid paclitaxel (LOCAL-TAX)
|
|
C. S. Zürn, K. Göhring-Frischholz, T. Hövelborn, A. May, M. Gawaz, C. Herdeg (Tübingen)
|
(P1329)
|
Mid-Term Clinical Outcome of CATANIA™ Coronary Stent System with Nanothin Polyzene®-F in a Real World Unselected Population: preliminary results
|
|
C. Nienaber, C. Tamburino, A. La Manna, D. Capodanno, M. E. Di Salvo, A. Sanfilippo (Rostock; Catania, IT)
|